. 2025 Mar 24;14(5):989–1003. doi: 10.1007/s40123-025-01130-1

Table 4.

In vivo release kinetics of travoprost intracameral implants

Time (months)^a	N	Mean (± SD) percent (%) remaining		Mean (± SD) cumulative percent (%) release
Time (months)^a	N	Travoprost	Travoprost + TFA^b	Travoprost	Travoprost + TFA^b
3	29	78.8 ± 3.15	79.9 ± 3.31	21.2 ± 3.15	20.1 ± 3.31
6	28	69.8 ± 8.51	72.1 ± 4.62	30.2 ± 8.51	27.9 ± 4.62
12	29	50.2 ± 6.58	52.0 ± 6.84	49.8 ± 6.58	48.0 ± 6.84
15	28	38.6 ± 8.23	41.6 ± 5.08	61.4 ± 8.23	58.4 ± 5.08
18	29	34.8 ± 7.09	35.6 ± 7.52	65.2 ± 7.09	64.4 ± 7.52
21	27	28.0 ± 5.76	28.6 ± 5.90	72.0 ± 5.76	71.4 ± 5.90
24	25	16.3 ± 7.88	16.8 ± 7.95	83.7 ± 7.88	83.2 ± 7.95

SD Standard deviation, TFA travoprost free acid

^aDuration from the time of administration of travoprost intracameral implant at visit 2 (first operative day 0) until the exchange procedure and collection of aqueous humor sample

^bData represent a summation of travoprost (prodrug) and TFA (active metabolite) percent release